3Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility tesing [S]. Seventeenth Informational Supplement. M100-S17. CLSI, 2007.
4Mutnick AH, Rhomberg PR, Sader HS, et al. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America(1999-2001)[J].J Antimicrob Chemother, 2004,53(2) :2901.
5Siroy A, Mdle V, Lemaitre Guillier C, et al. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein ofAcinetobacterbaumannii[J]. Antimicro Agents Chemother,2005,49(12) :4876-4883.
6Clinical and Laboratory Standards Institute(CLSI). Performance Standards for Antimicrobial susceptibility testing[S]. 2007.
7Rodriguez-Bano J, Paterson DL. A change in the epidemicology of infections due to exterded spectrum β-lactamase producing organisms[J]. Clin Infect Dis, 2006,42(7) :935-937.
8Paterson DL. The epidemiological profile of infections with multidrug resistant Preudomonas aeruginosa and Acinetobacter species[J]. Clin Infect Dis ,2006, 43(suppl 2):S43-S48.
9Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa[J].Clin Infect Dis, 2006, 43(suppl 2):S49-S56.
10Zavascki AP, Goldani LZ, Li J, et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review[J].J Anitmicrob Chemother, 2007, 60(6) : 1206-1215.
